Ticker

Biofrontera (NASDAQ: BFRI) reported record revenue for both the fourth quarter and full year 2025, driven by higher Ameluz photodynamic therapy (PDT) demand and a major change to its U.S. rights and supply economics following an amended arrangement with former parent Biofrontera AG. Record revenue and a profitable fourth quarter CEO Hermann Luebbert said fiscal 2025

Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update.…

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company…

Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.